There are 2949 resources available
1025MO - First-in-human (FIH) phase I study of RO7122290 (RO), a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab (ATZ) to patients with advanced solid tumours
Presenter: Ignacio Melero
Session: Mini Oral - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1026MO - Phase Ib dose escalation study of novel immunogenic cell death (ICD) inducer PT-112 plus PD-L1 inhibitor avelumab in solid tumours
Presenter: Daniel Karp
Session: Mini Oral - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
365MO - Exploring changes in glioblastoma treatment patterns in Europe and the USA with population-based cancer registry data
Presenter: Francesco Giusti
Session: Mini Oral - CNS
Resources:
Abstract
Slides
Webcast
366MO - Incidence of malignant and non-malignant CNS tumours in Hong Kong
Presenter: Ka Man Cheung
Session: Mini Oral - CNS
Resources:
Abstract
Slides
Webcast
369MO - Final results of depatuxizumab mafodotin plus temozolomide in recurrent glioblastoma patients: Real-world experience from a multicenter study of Italian Association of Neuro-Oncology (AINO)
Presenter: Marta Padovan
Session: Mini Oral - CNS
Resources:
Abstract
Slides
Webcast
ESMO Presidential address
Presenter: Solange Peters
Session: ESMO Virtual Congress 2020 Opening ceremony
Resources:
Webcast
COVID-19: Public health and scientific challenges
Presenter: Anthony Fauci
Session: ESMO Virtual Congress 2020 Opening ceremony
Resources:
Slides
Webcast
Highlights of the Science weekend
Presenter: John Haanen
Session: ESMO Virtual Congress 2020 Opening ceremony
Resources:
Slides
Webcast
How T cells induce cancer regressions
Presenter: Antoni Ribas
Session: ESMO Virtual Congress 2020 Opening ceremony
Resources:
Slides
Webcast
Invited Discussant 1214O and 1215O
Presenter: Lyudmila Bazhenova
Session: Proffered Paper - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast